PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN, TLC-ART-101, NDB-COMPOUNDS, SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF MITOCHONDRIAL TOXICITY ASSAYS

国家过敏和传染病研究所、国家卫生研究所、卫生和人类服务部获得性免疫缺陷综合征处持有一系列合同，以支持开发（1）艾滋病毒感染及其并发症和合并感染的疗法，以及（2）预防艾滋病毒性传播的杀微生物剂。根据这些合同提供的服务有助于学术机构和小型制药公司的研究人员填补其药物开发计划中的具体空白，因为他们将其产品推向艾滋病毒感染治疗和预防艾滋病毒传播干预措施的临床研究。活动将包括开发潜在治疗剂和杀微生物剂的配方。此外，还将进行研究，以评估潜在治疗剂和杀微生物剂的药理学和毒理学。 本活动的目的是进行阿米卡星、tlc-art-101、ndb化合物和舒特唑胺的药理学和毒理学研究，并支持线粒体毒性试验的开发。

The Division of Acquired Immunodeficiency Syndromes (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), maintains a portfolio of contracts to support the development of (1) therapies for HIV infection and its complications and coinfections, and (2) microbicides for preventing the sexual transmission of HIV. Services provided under this contracts assist investigators in academic settings and small pharmaceutical firms in filling specific gaps in their drug development plan as they advance their product towards clinical investigation of therapies for HIV infection and interventions to prevent HIV transmission. Activities will include the development of formulations of potential therapeutic agents and microbicides. In addition studies will be conducted to assess the pharmacology and toxicology of potential therapeutic agents and microbicides. The purpose of this activity is to conduct pharmacology and toxicology studies of amikacin, tlc-art-101, ndb-compounds, sutezolid, and support the development of mitochondrial toxicity assays.